Enlivex Therapeutics (ENLV) Investor presentation summary

Dual engine business model

• Combines advanced clinical-stage immunotherapy for age-related osteoarthritis with a digital asset treasury powered by prediction markets, aiming to extend both healthspan and wealthspan as global populations age.

• Utilizes Allocetra™, an off-the-shelf cell therapy, to target pain, mobility, and independence in aging populations, with strong clinical results supporting late-stage development.

• Leverages a large holding of RAIN, the leading prediction market token, to generate non-dilutive capital through deflationary tokenomics and active yield strategies.

• Holds an exclusive option to acquire up to $898 million in RAIN tokens at a fixed price, providing significant upside and anti-dilutive benefits for shareholders.

• Treasury value as of May 2026 is approximately $1 billion, with derivative instruments valued at $2.6 billion.

Prediction markets and RAIN ecosystem

• RAIN is a decentralized, permissionless prediction market protocol with a hybrid AI-human oracle and full builder infrastructure, enabling exponential ecosystem growth.

• Protocol features a 5% fee split between participation rewards and a buyback-and-burn mechanism, reducing token supply and benefiting holders.

• Forecasts project $2.5 billion in cumulative RAIN supply reduction by 2030, with prediction markets expected to reach $1 trillion in trading volume.

• RAIN is listed on major exchanges, enhancing liquidity and accessibility for institutional and global traders.

• Ongoing ecosystem expansion includes grants, new apps, liquidity injections, and strategic partnerships.

Clinical and market opportunity

• Osteoarthritis is the leading cause of disability, with a growing market expected to reach $15.78 billion by 2030.

• Allocetra™ demonstrated statistically significant, durable improvements in pain and function for knee osteoarthritis patients, especially in older age groups.

• Phase IIb global trial underway, targeting patients over 64, with topline data expected in 2027 to support a pivotal Phase 3 study.

• Platform has potential for multiple indications, with a scalable, cost-effective manufacturing process and favorable safety profile.

• Management team has a strong track record in drug development, regulatory approvals, and value creation.